VESICULAR FORMULATIONS CONTAINING ORGANIC ACID PRODRUGS, PROCESS FOR THEIR PREPARATION
申请人:Constantino Luis Filipe Vicente
公开号:US20100221315A1
公开(公告)日:2010-09-02
The present invention relates to vesicular formulations containing a prodrug, characterized for comprising the combination of a prodrug of weak organic acids having the following general formula: R
1
COOH (I) or R
1
SO
2
H (II) wherein R
1
is preferably selected from the group containing a benzenic, pyridinic, pyrazinic or pyrimidinic aromatic ring, or a linear chain substituted or unsubstituted, saturated or unsaturated, such as benzoic, benzenesulphinic, cinnamic, salicylic, pyrazinoic, nicotinic, carboxylic pyridazine and carboxylic pyrimidine, caproic, caprylic, capric, lauric, myristic, palmitic and estearic acids; with a liposomal or micellar carrier, which protects the prodrug from plasma degradation. The invention further relates to the process of preparation of liposomal formulations, novel prodrugs and pharmaceutical compositions intended for use in the treatment of tuberculosis and other mycobacterioses.
本发明涉及含有前药的囊泡制剂,其特征在于包括弱有机酸的前药的组合物,其具有以下一般式:R1COOH(I)或R1SO2H(II),其中R1最好选自包含苯环、吡啶环、吡嗪环或嘧啶环的群体,或取代或未取代的线性链,饱和或不饱和,例如苯甲酸、苯磺酸、肉桂酸、水杨酸、吡嗪酸、烟酸、羧基吡嗪和羧基嘧啶、己酸、辛酸、癸酸、月桂酸、肉豆蔻酸、棕榈酸和硬脂酸;与脂质体或胶束载体相结合,以保护前药不受血浆降解。本发明还涉及脂质体制剂的制备过程、新型前药和用于治疗结核病和其他分枝杆菌感染的药物组合物。